Generic Name:
Abemaciclib
Project Status:
Complete
Therapeutic Area:
Metastatic Breast Cancer
Manufacturer:
Eli Lilly Canada Inc.
Brand Name:
Verzenio
Project Line:
Reimbursement Review
Project Number:
PC0161-000
NOC Date:
Details
Strength:
50 mg, 100 mg, 150 mg and 200 mg
Tumour Type:
Breast
Indications:
Advanced or metastatic breast cancer
Funding Request:
For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer: • In combination with an aromatase inhibitor in postmenopausal women as initial endocrine based therapy. • In combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone agonist.
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Eli Lilly Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request:
For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer: • In combination with an aromatase inhibitor in postmenopausal women as initial endocrine based therapy. • In combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone agonist.
pERC Meeting:
Final Recommendation Issued: